Quick Order

Home>CD59
Text Size:AAA

CD59  Protein, Antibody, ELISA Kit, cDNA Clone

Expression host: Human Cells  
12474-H08H-50
12474-H08H-100
50 µg 
100 µg 
Add to Cart
  • Slide 1
Expression host: Human Cells  
80299-R02H-20
80299-R02H-100
20 µg 
100 µg 
Add to Cart
  • Slide 1
Expression host: Human Cells  
80299-R08H-20
80299-R08H-100
20 µg 
100 µg 
Add to Cart
  • Slide 1
Expression host: Human Cells  
90188-C08H-50
90188-C08H-100
50 µg 
100 µg 
Add to Cart
  • Slide 1

CD59 Related Area

CD59 Related Pathways

CD59 Related Protein, Antibody, cDNA Gene, and ELISA Kits

CD59 Related Protein, Antibody, cDNA Gene, and ELISA Kits

Featured Reagent Products

CD59 Summary & Protein Information

CD59 Background

Subunit structure: Interacts with T-cell surface antigen CD2. {ECO:0000269|PubMed:1377690}.
Subcellular location: Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Note=Soluble form found in a number of tissues.
Post-translational: N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine. Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants. {ECO:0000269|PubMed:18780401, ECO:0000269|PubMed:8670172}.; Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.
Involvement in disease: DISEASE: Hemolytic anemia, CD59-mediated, with or without polyneuropathy (HACD59) [MIM:612300]: An autosomal recessive disorder characterized by infantile onset of chronic hemolysis and a relapsing-remitting polyneuropathy, often exacerbated by infection, and manifested as hypotonia, limb muscle weakness, and hyporeflexia. {ECO:0000269|PubMed:1382994, ECO:0000269|PubMed:23149847}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Sequence similarity: Contains 1 UPAR/Ly6 domain. {ECO:0000305}.
General information above from UniProt

CD59 glycoprotein, also known as 20 kDa homologous restriction factor, HRF20, MAC-inhibitory protein, Membrane attack complex inhibition factor, Membrane inhibitor of reactive lysis, MIC11, MIRL and CD59, is a cell membrane protein which contains one UPAR/Ly6 domain. CD59 is a small, highly glycosylated, GPI-linked protein, with a wide expression profile. The soluble form of CD59 from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes. CD59 is a potent inhibitor of the complement membrane attack complex (MAC) action. CD59 was first identified as a regulator of the terminal pathway of complement. It acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. CD59 is involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase. Defects in CD59 are the cause of CD59 deficiency (CD59D).

CD59 Alternative Name

Cd59,16.3A5,1F5,EJ16,EJ30,EL32,FLJ38134,FLJ92039,G344,HRF20,HRF-20,MACIF,MAC-IP,MEM43,MGC2354,MIC11,MIN1,MIN2,MIN3,MIRL,MSK21,p18-20, [human]
AA987121,CD59,Cd59a,protectin,RP24-297H17.1, [mouse]

CD59 Related Studies

  • Fletcher CM. et al., 1994, Structure. 2: 185-99.
  • Rudd PM. et al., 1997, J Biol Chem. 272: 7229-44.
  • Kimberley FC. et al., 2007, Mol Immunol. 44 (1-3): 73-81.
  • Gong Y. et al., 2007, Sci China C Life Sci. 50 (6): 773-9.
  • Picariello G. et al., 2008, Proteomics 8: 3833-47.
  • Heibeck TH. et al., 2009, J Proteome Res. 8: 3852-61.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"